Muna Therapeutics
Muna Therapeutics is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Muna Therapeutics.
Muna Therapeutics is a technology company.
Key people at Muna Therapeutics.
Key people at Muna Therapeutics.
Muna Therapeutics is a privately held, IND-stage biopharmaceutical company founded in 2020, focused on discovering and developing transformative small molecule therapeutics for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, as well as autoimmune conditions.[1][2][3][4] The company targets neuronal dysfunction, neuroinflammation, and neuroprotection through an innovative all-in-human drug discovery platform that leverages insights from human brain cell types, high-resolution structural biology, AI-driven chemistry, and cell-based screening.[2][3] It serves patients with unmet needs in neurodegeneration, where no curative therapies exist, and has advanced to clinical stage with MNA-001, a novel oral TREM2 agonist in Phase 1 for early Alzheimer’s, dosing first subjects with topline data expected mid-2026.[5]
Muna Therapeutics emerged from the 2021 merger of two European startups: one founded in 2020 by progranulin pathway expert Professor Simon Glerup and his Aarhus University team, backed by Novo Holdings as part of its Novo Seeds company creation efforts, and K5 Therapeutics, co-founded that year by neurodegenerative pioneer Professor Bart De Strooper from VIB-KU Leuven, with Droia Ventures and VIB.[2][3] This combination formed Muna, headquartered in Copenhagen with sites in Leuven (Belgium) and the US, led by CEO Rita Balice-Gordon and COO Anders Hinsby, both Novo Seeds entrepreneurs-in-residence with deep pharma experience.[2][3] Early traction included a strategic partnership with Axxam SpA (Milan) as a minority shareholder and financing from Sanofi Ventures, Sofinnova Partners, Novo Holdings, and others to advance small molecule programs.[2][3]
Muna rides the wave of neurodegenerative disease innovation, targeting aging populations where Alzheimer’s and Parkinson’s affect millions with no disease-modifying cures amid rising prevalence.[3][4][5] Timing aligns with advances in human-derived insights, AI drug discovery, and microglial targets like TREM2, enabling resilience-focused therapies over traditional amyloid-beta approaches.[2][5] Market tailwinds include biotech funding for platform technologies and regulatory momentum for neurodegeneration (e.g., FDA’s Alzheimer’s focus), positioning Muna to influence the ecosystem by validating human brain cell pathways and accelerating small molecule pipelines.[2][3][5]
Muna’s Phase 1 initiation with MNA-001 marks its clinical pivot, with mid-2026 data potentially validating its resilience paradigm and unlocking further portfolio expansion in Alzheimer’s, Parkinson’s, and beyond.[5] Trends like AI-accelerated discovery, microglial modulation, and multi-target neurodegeneration strategies will propel growth, especially as partners like Sofinnova scale European biotech.[3] Its influence may evolve from platform pioneer to leader in protective therapies, bridging academic insights to impactful drugs and reshaping outcomes for millions—transforming "Muna" (Old Norse for "to remember") into clinical reality.[4][5]
